Imaging Markers of Progression in Parkinson's Disease

on behalf of IPMDS-Neuroimaging Study Group; Antonio P. Strafella; Nico I. Bohnen; Nicola Pavese; David E. Vaillancourt; Thilo van Eimeren; Marios Politis; Alessandro Tessitore; Christine Ghadery; Simon Lewis

doi:10.1002/mdc3.12673

Imaging Markers of Progression in Parkinson's Disease

on behalf of IPMDS-Neuroimaging Study Group, Antonio P. Strafella^*, Nico I. Bohnen, Nicola Pavese, David E. Vaillancourt, Thilo van Eimeren, Marios Politis, Alessandro Tessitore, Christine Ghadery, Simon Lewis

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

16 Citations (Scopus)

Abstract

Background

Parkinson's disease (PD) is the second‐most common neurodegenerative disorder after Alzheimer's disease; however, to date, there is no approved treatment that stops or slows down disease progression. Over the past decades, neuroimaging studies, including molecular imaging and MRI are trying to provide insights into the mechanisms underlying PD.

Methods

This work utilized a literature review.

Results

It is now becoming clear that these imaging modalities can provide biomarkers that can objectively detect brain changes related to PD and monitor these changes as the disease progresses, and these biomarkers are required to establish a breakthrough in neuroprotective or disease‐modifying therapeutics.

Conclusions

Here, we provide a review of recent observations deriving from PET, single‐positron emission tomography, and MRI studies exploring PD and other parkinsonian disorders.

Original language	English
Journal	Movement Disorders Clinical Practice
Early online date	9 Aug 2018
DOIs	https://doi.org/10.1002/mdc3.12673
Publication status	Published - 15 Aug 2018

Keywords

imaging biomarker
magnetic resonance imaging
molecular imaging
Parkinson's disease

Access to Document

10.1002/mdc3.12673

Cite this

@article{88969765259a401a9e68f70a0d902195,

title = "Imaging Markers of Progression in Parkinson's Disease",

abstract = "BackgroundParkinson's disease (PD) is the second‐most common neurodegenerative disorder after Alzheimer's disease; however, to date, there is no approved treatment that stops or slows down disease progression. Over the past decades, neuroimaging studies, including molecular imaging and MRI are trying to provide insights into the mechanisms underlying PD.MethodsThis work utilized a literature review.ResultsIt is now becoming clear that these imaging modalities can provide biomarkers that can objectively detect brain changes related to PD and monitor these changes as the disease progresses, and these biomarkers are required to establish a breakthrough in neuroprotective or disease‐modifying therapeutics.ConclusionsHere, we provide a review of recent observations deriving from PET, single‐positron emission tomography, and MRI studies exploring PD and other parkinsonian disorders.",

keywords = "imaging biomarker, magnetic resonance imaging, molecular imaging, Parkinson's disease",

author = "{on behalf of IPMDS-Neuroimaging Study Group} and Strafella, {Antonio P.} and Bohnen, {Nico I.} and Nicola Pavese and Vaillancourt, {David E.} and {van Eimeren}, Thilo and Marios Politis and Alessandro Tessitore and Christine Ghadery and Simon Lewis",

year = "2018",

month = aug,

day = "15",

doi = "10.1002/mdc3.12673",

language = "English",

journal = "Movement Disorders Clinical Practice",

issn = "2330-1619",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Imaging Markers of Progression in Parkinson's Disease

AU - on behalf of IPMDS-Neuroimaging Study Group

AU - Strafella, Antonio P.

AU - Bohnen, Nico I.

AU - Pavese, Nicola

AU - Vaillancourt, David E.

AU - van Eimeren, Thilo

AU - Politis, Marios

AU - Tessitore, Alessandro

AU - Ghadery, Christine

AU - Lewis, Simon

PY - 2018/8/15

Y1 - 2018/8/15

N2 - BackgroundParkinson's disease (PD) is the second‐most common neurodegenerative disorder after Alzheimer's disease; however, to date, there is no approved treatment that stops or slows down disease progression. Over the past decades, neuroimaging studies, including molecular imaging and MRI are trying to provide insights into the mechanisms underlying PD.MethodsThis work utilized a literature review.ResultsIt is now becoming clear that these imaging modalities can provide biomarkers that can objectively detect brain changes related to PD and monitor these changes as the disease progresses, and these biomarkers are required to establish a breakthrough in neuroprotective or disease‐modifying therapeutics.ConclusionsHere, we provide a review of recent observations deriving from PET, single‐positron emission tomography, and MRI studies exploring PD and other parkinsonian disorders.

AB - BackgroundParkinson's disease (PD) is the second‐most common neurodegenerative disorder after Alzheimer's disease; however, to date, there is no approved treatment that stops or slows down disease progression. Over the past decades, neuroimaging studies, including molecular imaging and MRI are trying to provide insights into the mechanisms underlying PD.MethodsThis work utilized a literature review.ResultsIt is now becoming clear that these imaging modalities can provide biomarkers that can objectively detect brain changes related to PD and monitor these changes as the disease progresses, and these biomarkers are required to establish a breakthrough in neuroprotective or disease‐modifying therapeutics.ConclusionsHere, we provide a review of recent observations deriving from PET, single‐positron emission tomography, and MRI studies exploring PD and other parkinsonian disorders.

KW - imaging biomarker

KW - magnetic resonance imaging

KW - molecular imaging

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85054687755&partnerID=8YFLogxK

U2 - 10.1002/mdc3.12673

DO - 10.1002/mdc3.12673

M3 - Review article

AN - SCOPUS:85054687755

SN - 2330-1619

JO - Movement Disorders Clinical Practice

JF - Movement Disorders Clinical Practice

ER -

Imaging Markers of Progression in Parkinson's Disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this